JPRN-jRCT2080221336未知3 期
ong-term administration study of KW-6485P for pediatric patients (extension from phase III study)
Kyowa Hakko Kirin Co., Ltd.0 个研究点目标入组 60 人开始时间: 2010年12月20日最近更新:
适应症
试验速览
- 阶段
- 3 期
- 发起方
- 入组人数
- 60
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- >= 2age old 至 <= 15age old（—）
- 性别
- All
入选标准
- •Patients who have completed the evaluation period for efficacy in the phase III study of KW-6485P
- •Patients who have provided written informed consent from guardian
排除标准
- •Patients who did not reliably complete their epileptic seizure record in the phase III study of KW-6485P
研究者
相似试验
未知
2 期
ong-term study of KW-6485PSymptomatic or cryptogenic localization related epilepsyJPRN-jRCT2080220855Kyowa Hakko Kirin Co., Ltd.25
未知
3 期
ong-Term Safety Study of KW-6002 (6002-010)Parkinson's DiseaseJPRN-jRCT2080220821Kyowa Hakko Kirin Co., Ltd.150
未知
3 期
Placebo-Controlled Double-Blind Crossover Comparative Study of KW-6500 (6500-004)Parkinson's DiseaseJPRN-jRCT2080220980Kyowa Hakko Kirin Co., Ltd.20
已完成
2 期
A Study of KW-6356 in Patients With Parkinson's Disease on Treatment With Levodopa-containing PreparationsParkinson's DiseaseJPRN-jRCT2080224050Kyowa Kirin Co., Ltd.486
未知
3 期
Phase III study of KW-6485P (6485P-004)JPRN-jRCT2080221158Kyowa Hakko Kirin Co., Ltd.60